Magnolol affects cellular growth and proliferation in human prostate\ncancer cells in vitro
Bibliographic record
Abstract
Prostate cancer is the most commonly diagnosed form of cancer in men in Canada and\nthe United States. Both genetic and environmental factors contribute to development and\nprogression of many cancers, including prostate cancer, with prostate cancer affecting\nmany men worldwide. As such there have been many studies into the effects of natural\nproducts on this form of cancer. This work demonstrates the effects of magnolol, a\ncompound found in the roots and bark of the magnolia tree Magnolia officinalis, on the\nbehavior of LNCaP, DU145 and PC3 human prostate cancer cells in vitro. Magnolol was\nfound to be cytotoxic to human prostate cancer cells, and to affect cell cycle progression\nof DU145 and PC3 cells, resulting in alterations to the cell cycle and subsequently\ndecreasing the proportion of cells entering the G2/M-phase of the cell cycle. Magnolol\ninhibited the expression of cell cycle regulatory proteins including cyclins A, B1, D1 and\nE, as well as CDK2 and CDK4. Protein expression levels of pRBp107 decreased, while\npRBp130 and p27 protein expression levels increased in response to magnolol exposure.\nPC3 cells exposed to magnolol exhibited decreased protein expression of ornithine\ndecarboxylase, a key regulator in polyamine biosynthesis, as well as affecting expression\nof other proteins involved in polyamine biosynthesis and catabolism. Furthermore,\nprotein expression of the R2 subunit of ribonucleotide reductase was significantly\ndecreased. Cellular signaling pathways were also assayed to determine which, if any, of\nthese pathways magnolol exposure would alter. Finally, magnolol was found to affect the\nexpression of IGF-I and associated proteins in LNCaP and PC3 cells. In both cell lines, protein expression of IGF-I and IGFBP-5 were significantly decreased while protein\nexpression of IGFBP-3 was significantly increased. The results obtained throughout this\nthesis suggest that magnolol can affect the behavior of human prostate cancer cells in\nvitro, suggesting that magnolol may have potential as a novel anti-prostate cancer agent.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".